Silver Book Fact

An Alzheimer’s treatment breakthrough that slowed disease progression and began to show effects in 2015, would reduce Medicaid costs for people with the disease by $62 billion–from the expected $178 billion to $116 billion.

Alzheimer's Association. Changing the Trajectory of Alzheimer’s Disease: How a treatment by 2025 saves lives and dollars. Washington, D.C.: Alzheimer’s Association; 2010. http://www.alz.org/documents_custom/trajectory.pdf

Reference

Title
Changing the Trajectory of Alzheimer’s Disease: How a treatment by 2025 saves lives and dollars
Publisher
Alzheimer’s Association
Publication Date
2010
Authors
Alzheimer's Association
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • The U.S. Food and Drug Administration has approved 5 drugs that have proven to temporarily slow the worsening of Alzheimer’s disease symptoms for an average of 6 – 12 months…  
  • Impact of a 5-Year Delay in Onset on Costs, Americans Age 65 and Older with Alzhemier’s Disease, 2010-2050  
  • Galantamine, a cholinesterase inhibitor, delays Alzheimer’s patients’ need for full-time care, with overall cost savings estimated between $323 and $4,256 per patient.  
  • If an Alzheimer’s disease treatment breakthrough that delayed the age of onset by 5 years was introduced in 2015, by 2020 out-of-pocket costs to individuals and families dealing with the…  
  • A medicine is in development that aims to prevent or reverse Alzheimer’s disease progression by using a human monoclonal antibody specifically designed to remove beta amyloid protein from the brain.